What Happened
A former nurse who worked at the Veterans Affairs Medical Center in Minneapolis was indicted on August 21, 2026, on one count of obtaining controlled substances by misrepresentation, fraud, forgery, deception, or subterfuge.
According to the federal indictment, the 58-year-old former nurse is alleged to have wrongfully obtained hydromorphone — a potent opioid — from in or about January 2025 through on or about January 28, 2026, a window of roughly 13 months. The initial appearance took place before a U.S. Magistrate Judge on August 21, 2026.
The case was announced by the U.S. Attorney's Office for the District of Minnesota and resulted from an investigation by the Department of Veterans Affairs Office of Inspector General, the VA Police Department, the Food and Drug Administration's Office of Criminal Investigations, and the DEA. The defendant is presumed innocent until proven guilty.
What Went Wrong
Charges in this case are allegations, not findings — but the pattern described is one diversion programs see repeatedly in inpatient settings:
- A prolonged, low-volume pattern. The alleged conduct spans about 13 months. Diversion that continues for that long usually sits below the threshold of a single dramatic event — it hides in day-to-day counts, waste documentation, and access patterns.
- Hydromorphone is a high-risk inpatient drug. Potent injectable opioids are prime diversion targets because partial doses, residual waste, and "wasted" amounts are easy to under-document when no one verifies the disposal.
- Theft by fraud rather than force. The charge — obtaining a controlled substance by misrepresentation, fraud, forgery, deception, or subterfuge (21 U.S.C. § 843(a)(3)) — is the classic CSA section for insiders who use their legitimate access dishonestly rather than breaking in.
- Federal health systems get the same scrutiny as everyone else. VA OIG, VA Police, FDA-OCI, and DEA all investigated — a reminder that diversion in federal facilities is investigated by multiple agencies with deep data-access capability.
How It Could Have Been Prevented
- Reconcile controlled substance counts and waste documentation regularly — daily for high-risk opioids on units where injectables are stocked — so a 13-month pattern surfaces in weeks, not a year.
- Verify waste documentation with a second person and spot-check "wasted" doses against dispensing records; unwitnessed or implausible waste is a leading diversion red flag.
- Audit access and transaction patterns for hydromorphone and other high-risk opioids — who withdraws, when, and whether the documented clinical need matches the pattern.
- Monitor behavioral red flags and route concerns through a documented review process rather than informal conversations.
- Remember that diversion programs apply to every caregiver with access — nurses, technicians, and pharmacists alike — and that federal and state investigators will expect to see documented responses to any flagged pattern.
Related Guidance
- Controlled Substance Inventory Guide — Reconciliation, cycle counts, and biennial inventory requirements for CSA registrants.
- Audit Pharmacy Tech Access Controls to Catch Diversion Early — How role-based access audits surface insider diversion.
- Waste Documentation Policies — Why waste records are the most commonly falsified diversion document.
- How to Report Drug Diversion — When and how to report theft or loss to the DEA.
- Browse All Diversion Case Studies — Real-world cases with prevention analysis.